Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
31 Aug 2022
31 Aug 2022
Historique:
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
epublish
Résumé
SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting strong immunity that is further boosted by previous infection. However, it is unclear whether these immune responses are affected by the interval between infection and vaccination. Over a two-month period, we evaluated antibody and B-cell responses to a third dose mRNA vaccine in 66 individuals with different infection histories. Uninfected and post-boost but not previously infected individuals mounted robust ancestral and variant spike-binding and neutralizing antibodies, and memory B cells. Spike-specific B-cell responses from recent infection were elevated at pre-boost but comparatively less so at 60 days post-boost compared to uninfected individuals, and these differences were linked to baseline frequencies of CD27
Identifiants
pubmed: 36093348
doi: 10.1101/2022.08.30.22279344
pmc: PMC9460969
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Références
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
PLoS One. 2022 May 24;17(5):e0268767
pubmed: 35609088
Immunity. 2022 Jun 14;55(6):945-964
pubmed: 35637104
J Exp Med. 2013 Mar 11;210(3):457-64
pubmed: 23420879
Cell. 2020 Jan 9;180(1):92-106.e11
pubmed: 31866068
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
Cell. 2022 Apr 28;185(9):1556-1571.e18
pubmed: 35447072
Immunity. 2018 Oct 16;49(4):725-739.e6
pubmed: 30314758
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
F1000Prime Rep. 2013 Oct 01;5:40
pubmed: 24167721
Curr Opin Rheumatol. 2019 Mar;31(2):175-184
pubmed: 30540579
Protein Expr Purif. 2021 Mar;179:105802
pubmed: 33248226
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Exp Med. 2022 Jun 6;219(6):
pubmed: 35420627
Cell Rep. 2023 Mar 28;42(3):112167
pubmed: 36857186
Annu Rev Immunol. 2021 Apr 26;39:103-129
pubmed: 33472004
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Nat Rev Immunol. 2022 Jan;22(1):7-18
pubmed: 34873279
Sci Immunol. 2022 Apr 22;7(70):eabn8590
pubmed: 35113654
Nat Rev Immunol. 2022 Feb;22(2):69-71
pubmed: 35046570
Immunity. 2019 Aug 20;51(2):398-410.e5
pubmed: 31350180
Cell. 2022 Apr 28;185(9):1588-1601.e14
pubmed: 35413241
Nat Immunol. 2020 Dec;21(12):1506-1516
pubmed: 33028979
J Exp Med. 2011 Dec 19;208(13):2599-606
pubmed: 22162833
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Immunol. 2018 Sep;19(9):1001-1012
pubmed: 30104633
Sci Transl Med. 2021 Jul 7;13(601):
pubmed: 34158410
Cell. 2022 Jul 7;185(14):2434-2451.e17
pubmed: 35764089
Protein Expr Purif. 2020 Oct;174:105686
pubmed: 32504802
Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2204607119
pubmed: 35759653
Science. 2022 Jul 15;377(6603):eabq1841
pubmed: 35699621
Nature. 2021 Dec;600(7889):530-535
pubmed: 34670266
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Cell. 2022 May 26;185(11):1875-1887.e8
pubmed: 35523182